Neurology · PANCE / PANRE

Ischemic Stroke

Acute focal neurologic deficit from arterial occlusion causing brain infarction.

Also known as: CVA, cerebral infarction, brain attack, thromboembolic stroke, large vessel occlusion, LVO

Overview

Acute focal neurologic deficit lasting >24 hours (or imaging-confirmed infarction at any duration) caused by interruption of cerebral arterial blood flow with resulting tissue ischemia and infarction.

Epidemiology

Fifth leading cause of death in the US and a leading cause of long-term disability. ~87% of all strokes are ischemic. Incidence rises sharply after age 55, doubling each decade.

🔒 Free preview limit reached

Keep reading — start your free trial

You've read your 2 free diagnosis previews. Create your free account to unlock the full Ischemic Stroke outline — plus all 514 diagnoses, 3,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.

Free to start · No credit card · Cancel anytime

Risk factors

  • Non-modifiable: age, male sex (until later life), family history, prior stroke/TIA, sickle cell disease
  • Modifiable: hypertension (strongest modifiable risk), diabetes, dyslipidemia, smoking, atrial fibrillation, carotid stenosis, obesity, OSA, physical inactivity
  • Other: hypercoagulable states (antiphospholipid syndrome, malignancy), oral contraceptives + smoking in women >35, cocaine/methamphetamine use, recent MI with mural thrombus, PFO (paradoxical embolism)

Pathophysiology

Occlusion of a cerebral artery by thrombus (in-situ atherosclerosis) or embolus (cardioembolic or artery-to-artery) reduces regional cerebral blood flow below the threshold for neuronal function (~20 mL/100 g/min) and then below the threshold for cellular integrity (~10 mL/100 g/min). The irreversibly infarcted core is surrounded by an ischemic penumbra of stunned but viable tissue maintained by collateral flow. Reperfusion within the therapeutic window can salvage the penumbra; without it the infarct expands.

Clinical presentation

Symptoms

  • Sudden, focal neurologic deficit: unilateral weakness, sensory loss, aphasia, dysarthria, gaze deviation, hemianopia, ataxia, vertigo
  • Symptoms maximal at onset (contrast with progressive course of tumor)
  • Headache uncommon (more typical of hemorrhagic or vertebrobasilar territory)

Signs / physical exam

  • MCA syndrome: contralateral face/arm > leg weakness, aphasia (dominant) or neglect (non-dominant), gaze deviation toward lesion
  • ACA syndrome: contralateral leg > arm weakness, abulia, urinary incontinence
  • PCA syndrome: contralateral homonymous hemianopia, alexia without agraphia (dominant)
  • Lacunar syndromes: pure motor, pure sensory, ataxic hemiparesis, dysarthria-clumsy hand
  • Posterior circulation: vertigo, diplopia, dysphagia, crossed signs (ipsilateral face / contralateral body)

Classic findings

Sudden onset focal deficit referable to a single vascular territory; NIHSS quantifies severity (0-42).

Differential diagnosis

  • Hemorrhagic stroke (ICH) — Indistinguishable clinically — non-contrast head CT differentiates; headache, vomiting, and rapidly declining consciousness more common with ICH
  • TIA — Same clinical syndrome but symptoms resolve completely, usually <1 hour; no infarction on imaging
  • Seizure with Todd paralysis — Postictal focal weakness lasting minutes to ~48 h; witnessed convulsion or tongue bite favor this
  • Hypoglycemia — Can mimic any focal deficit; fingerstick glucose mandatory before tPA — D50 if <60 mg/dL
  • Complex migraine (hemiplegic migraine) — Younger patient, headache prominent, spreading march of symptoms over minutes, prior similar episodes
  • Conversion disorder / functional — Inconsistent exam, non-anatomic distribution, normal imaging — diagnosis of exclusion
  • Brain tumor / abscess — Subacute progression over days-weeks; CT/MRI with contrast diagnostic
  • Bell palsy — Isolated peripheral CN VII palsy involving the forehead; central facial sparing involves lower face only

Diagnostic workup

Diagnostic criteria

Clinical syndrome of acute focal neurologic deficit with imaging evidence of infarction (CT hypodensity or MRI DWI restriction) and exclusion of hemorrhage.

Labs

  • Fingerstick glucose immediately (rule out hypoglycemia)
  • CBC, platelets, PT/INR, PTT, BMP, troponin
  • Lipid panel, A1c — for secondary prevention
  • Pregnancy test in women of childbearing age

Imaging

  • Non-contrast head CT within 20 min of arrival — excludes hemorrhage (essential before tPA)
  • CT angiography head and neck — identifies large vessel occlusion candidates for thrombectomy
  • CT perfusion or MR diffusion/perfusion — quantifies core vs penumbra for extended-window thrombectomy (DAWN, DEFUSE-3)
  • MRI with DWI — most sensitive for acute infarction (positive within minutes)
  • Carotid duplex, transthoracic or transesophageal echo, telemetry/Holter (AFib detection) for etiology

Diagnostic algorithm

flowchart TD
  A[Acute focal deficit<br/>Last known well documented] --> B[Glucose + NIHSS]
  B --> C[Non-contrast head CT<br/>≤20 min]
  C --> D{Hemorrhage?}
  D -->|Yes| E[Hemorrhagic pathway<br/>BP control, reverse anticoag]
  D -->|No| F{Within 4.5 h<br/>+ no contraindications?}
  F -->|Yes| G[IV alteplase 0.9 mg/kg<br/>or tenecteplase]
  F -->|No| H[Aspirin 325 mg<br/>secondary prevention]
  G --> I[CTA head/neck]
  H --> I
  I --> J{LVO present?}
  J -->|Yes, ≤24 h + favorable imaging| K[Mechanical thrombectomy]
  J -->|No| L[Stroke unit admission<br/>workup etiology]
  K --> L
Acute ischemic stroke triage — time-critical pathway from arrival to reperfusion therapy.

Treatment

First-line

  • tPA dosing — alteplase 0.9 mg/kg IV (max 90 mg), 10% as bolus over 1 min, remainder over 60 min, if within 4.5 h of last known well and no contraindications (NINDS, ECASS III)
  • Tenecteplase 0.25 mg/kg IV bolus — increasingly used alternative, particularly with LVO bridging to thrombectomy
  • Mechanical thrombectomy for anterior circulation LVO within 6 h (standard) or up to 24 h if favorable perfusion imaging (DAWN, DEFUSE-3)
  • BP target: <185/110 before tPA; <180/105 for 24 h after tPA; otherwise permissive HTN <220/120 unless end-organ injury
  • Aspirin 325 mg within 24-48 h (delay 24 h after tPA)
  • DVT prophylaxis (mechanical immediately; chemical after 24 h if no hemorrhage)

Second-line / adjunct

  • Dual antiplatelet therapy (aspirin + clopidogrel) for 21-90 days after minor stroke/high-risk TIA (CHANCE, POINT) then aspirin monotherapy
  • High-intensity statin: atorvastatin 80 mg daily (SPARCL)
  • Anticoagulation (warfarin, DOAC — apixaban, rivaroxaban, dabigatran, edoxaban) for cardioembolic stroke from AFib; typically start 4-14 days post-stroke based on infarct size
  • Carotid endarterectomy or stenting if ipsilateral carotid stenosis 70-99% (symptomatic) — within 2 weeks
  • Blood pressure control (goal <130/80), diabetes control, smoking cessation, stroke rehab

Complications

  • Hemorrhagic transformation (especially after tPA, large infarct, or reperfusion)
  • Cerebral edema with herniation (large MCA or cerebellar stroke; may need hemicraniectomy)
  • Aspiration pneumonia (screen swallow before any oral intake)
  • DVT/PE, UTI, decubitus ulcers from immobility
  • Post-stroke depression, spasticity, seizures, vascular dementia
  • Recurrent stroke (highest risk in first 90 days)

PANCE pearls

  • BE-FAST: Balance, Eyes, Face, Arm, Speech, Time — public stroke recognition mnemonic.
  • tPA absolute contraindications: ICH ever, recent (<3 mo) head trauma/stroke/intracranial surgery, active bleeding, platelets <100k, INR >1.7, BP >185/110 refractory to treatment.
  • Wake-up strokes with favorable MRI mismatch (DWI positive, FLAIR negative — 'WAKE-UP' trial) may still be tPA candidates.
  • Posterior circulation stroke is frequently misdiagnosed as labyrinthitis; HINTS exam (Head Impulse, Nystagmus, Test of Skew) distinguishes central from peripheral vertigo.
  • Young stroke workup: hypercoagulable panel, vasculitis serologies, drug screen, echo with bubble study for PFO, vertebral artery dissection imaging.

References

  • AHA/ASA 2019 — Guidelines for the Early Management of Patients With Acute Ischemic Stroke (Powers et al., Stroke 2019, 2019 update)
  • NINDS Trial — Tissue Plasminogen Activator for Acute Ischemic Stroke (NINDS rt-PA Study Group, NEJM 1995)
  • ECASS III — Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke (Hacke et al., NEJM 2008)
  • DAWN Trial — Thrombectomy 6 to 24 Hours after Stroke with a Mismatch (Nogueira et al., NEJM 2018)
  • DEFUSE 3 — Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging (Albers et al., NEJM 2018)

Practice Neurology questions on FirstPassPA

Turn this outline into retention. 3,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.

Start studying free → Browse all 514 diagnoses

Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants.